204 related articles for article (PubMed ID: 12456630)
1. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor.
Bladbjerg EM; Skouby SO; Andersen LF; Jespersen J
Hum Reprod; 2002 Dec; 17(12):3235-41. PubMed ID: 12456630
[TBL] [Abstract][Full Text] [Related]
2. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations.
Skouby SO; Gram J; Andersen LF; Sidelmann J; Petersen KR; Jespersen J
Am J Obstet Gynecol; 2002 May; 186(5):969-77. PubMed ID: 12015523
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.
Taskinen MR; Puolakka J; Pyörälä T; Luotola H; Bjäörn M; Kääriänen J; Lahdenperä S; Ehnholm C
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1215-21. PubMed ID: 8857916
[TBL] [Abstract][Full Text] [Related]
4. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study.
Perera M; Sattar N; Petrie JR; Hillier C; Small M; Connell JM; Lowe GD; Lumsden MA
J Clin Endocrinol Metab; 2001 Mar; 86(3):1140-3. PubMed ID: 11238498
[TBL] [Abstract][Full Text] [Related]
5. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.
Davidson MH; Maki KC; Marx P; Maki AC; Cyrowski MS; Nanavati N; Arce JC
Arch Intern Med; 2000 Nov; 160(21):3315-25. PubMed ID: 11088095
[TBL] [Abstract][Full Text] [Related]
6. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII.
Peverill RE; Teede HJ; Smolich JJ; Malan E; Kotsopoulos D; Tipping PG; McGrath BP
Clin Sci (Lond); 2001 Jul; 101(1):93-9. PubMed ID: 11410120
[TBL] [Abstract][Full Text] [Related]
7. Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1.
Borgfeldt C; Li C; Samsioe G
Climacteric; 2004 Mar; 7(1):78-85. PubMed ID: 15259286
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy and risk of breast cancer: the role of progestins.
Stahlberg C; Pederson AT; Lynge E; Ottesen B
Acta Obstet Gynecol Scand; 2003 Jul; 82(7):335-44. PubMed ID: 12790856
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate.
Imthurn B; Rosselli M; Jaeger AW; Keller PJ; Dubey RK
J Clin Endocrinol Metab; 1997 Feb; 82(2):388-94. PubMed ID: 9024224
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers.
Stevenson JC; Oladipo A; Manassiev N; Whitehead MI; Guilford S; Proudler AJ
Br J Haematol; 2004 Mar; 124(6):802-8. PubMed ID: 15009069
[TBL] [Abstract][Full Text] [Related]
11. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis.
Teede HJ; McGrath BP; Smolich JJ; Malan E; Kotsopoulos D; Liang YL; Peverill RE
Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1404-9. PubMed ID: 10807761
[TBL] [Abstract][Full Text] [Related]
12. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
13. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
Odmark IS; Bäckström T; Haeger M; Jonsson B; Bixo M
Maturitas; 2004 Jun; 48(2):137-46. PubMed ID: 15172088
[TBL] [Abstract][Full Text] [Related]
14. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
15. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study.
Bruhat M; Rudolf K; Vaheri R; Kainulainen P; Timonen U; Viitanen A
Maturitas; 2001 Dec; 40(3):259-71. PubMed ID: 11731187
[TBL] [Abstract][Full Text] [Related]
16. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors.
Andersen LF; Gram J; Skouby SO; Jespersen J
Am J Obstet Gynecol; 1999 Feb; 180(2 Pt 1):283-9. PubMed ID: 9988788
[TBL] [Abstract][Full Text] [Related]
17. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
Høibraaten E; Qvigstad E; Andersen TO; Mowinckel MC; Sandset PM
Thromb Haemost; 2001 May; 85(5):775-81. PubMed ID: 11372667
[TBL] [Abstract][Full Text] [Related]
18. Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women.
Dören M; Schneider HP
Maturitas; 1996 Oct; 25(2):99-105. PubMed ID: 8905600
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study.
Sidelmann JJ; Jespersen J; Andersen LF; Skouby SO;
BJOG; 2003 Jun; 110(6):541-7. PubMed ID: 12798469
[TBL] [Abstract][Full Text] [Related]
20. Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate.
Lundström E; Virijevic I; Söderqvist G
Horm Mol Biol Clin Investig; 2020 Jul; 41(3):. PubMed ID: 32735552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
